Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elodie Alessandri-Gradt

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Viruses|March 30, 2023
HIV-1 Non-Group M Strains and ARTElodie Alessandri-Gradt, Alice Moisan, Jean-Christophe Plantier
The Journal of Antimicrobial Chemotherapy|April 30, 2022
Bictegravir-based antiretroviral therapy in HIV-1 group O patients: data from real-life bictegravir/emtricitabine/tenofovir alafenamide switchesCharlène Martin, Guillemette Unal, Jean Christophe Plantier, et al.
AIDS (London, England)|April 6, 2019
Virological response to integrase strand transfer inhibitor-based antiretroviral combinations in HIV-1 group O-infected patientsElodie Alessandri-Gradt, Guillemette Unal, Marie Leoz, et al.
Journal of Clinical Microbiology|February 26, 2016
A Multiplex PCR Approach for Detecting Dual Infections and Recombinants Involving Major HIV VariantsPierre Cappy, Fabienne De Oliveira, Marie Gueudin, et al.
The Journal of Antimicrobial Chemotherapy|July 23, 2018
Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavirElodie Alessandri-Gradt, Charlotte Charpentier, Marie Leoz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 10, 2021
Performance Analysis of Three Commercial Kits Designed for RNA Quantification of HIV-1 Group O VariantsElodie Alessandri-Gradt, Guillemette Unal, Adeline Baron, et al.
Scientific Reports|January 19, 2024
In vitro replicative potential of an HIV-1/MO intergroup recombinant virus compared to HIV-1/M and HIV-1/O parental virusesAlice Moisan, Fabienne Tombette, Manon Vautrin, et al.
The Journal of Antimicrobial Chemotherapy|May 19, 2026
Early bictegravir failure and emergence of R263K-mediated class-wide HIV integrase inhibitors resistance linked to over-the-counter supplement useElisa Minacori, Anaïs Lesourd, Camille Molkhou, et al.
AIDS (London, England)|June 3, 2015
HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group MElodie Alessandri-Gradt, Marjolaine Morgand, Constance Delaugerre, et al.
Journal of Medical Virology|April 11, 2026
HIV-1 Non Group-M Phenotypic Susceptibility to IbalizumabLucie Poisson, Quentin Le Hingrat, Fanny Lermechain, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Viruses|March 30, 2023
HIV-1 Non-Group M Strains and ARTElodie Alessandri-Gradt, Alice Moisan, Jean-Christophe Plantier
The Journal of Antimicrobial Chemotherapy|April 30, 2022
Bictegravir-based antiretroviral therapy in HIV-1 group O patients: data from real-life bictegravir/emtricitabine/tenofovir alafenamide switchesCharlène Martin, Guillemette Unal, Jean Christophe Plantier, et al.
AIDS (London, England)|April 6, 2019
Virological response to integrase strand transfer inhibitor-based antiretroviral combinations in HIV-1 group O-infected patientsElodie Alessandri-Gradt, Guillemette Unal, Marie Leoz, et al.
Journal of Clinical Microbiology|February 26, 2016
A Multiplex PCR Approach for Detecting Dual Infections and Recombinants Involving Major HIV VariantsPierre Cappy, Fabienne De Oliveira, Marie Gueudin, et al.
The Journal of Antimicrobial Chemotherapy|July 23, 2018
Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavirElodie Alessandri-Gradt, Charlotte Charpentier, Marie Leoz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 10, 2021
Performance Analysis of Three Commercial Kits Designed for RNA Quantification of HIV-1 Group O VariantsElodie Alessandri-Gradt, Guillemette Unal, Adeline Baron, et al.
Scientific Reports|January 19, 2024
In vitro replicative potential of an HIV-1/MO intergroup recombinant virus compared to HIV-1/M and HIV-1/O parental virusesAlice Moisan, Fabienne Tombette, Manon Vautrin, et al.
The Journal of Antimicrobial Chemotherapy|May 19, 2026
Early bictegravir failure and emergence of R263K-mediated class-wide HIV integrase inhibitors resistance linked to over-the-counter supplement useElisa Minacori, Anaïs Lesourd, Camille Molkhou, et al.
AIDS (London, England)|June 3, 2015
HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group MElodie Alessandri-Gradt, Marjolaine Morgand, Constance Delaugerre, et al.
Journal of Medical Virology|April 11, 2026
HIV-1 Non Group-M Phenotypic Susceptibility to IbalizumabLucie Poisson, Quentin Le Hingrat, Fanny Lermechain, et al.
Pageof 4